About Diagnexia
Diagnexia operates as a comprehensive digital pathology department, connecting healthcare organisations with an international network of GMC-registered, subspecialty-trained pathologists. The company provides end-to-end histopathology services including primary diagnostic reporting, secondary expert consultations, and External Quality Assurance (EQA) programmes. Founded to address the critical pathology workforce shortage, Diagnexia combines digital pathology infrastructure with expert clinical capacity to help NHS trusts and health systems clear backlogs, balance workloads, and improve patient outcomes. The platform features fully digital workflows with integrated synoptic reporting, seamless LIS integration, and comprehensive case management. Diagnexia maintains UKAS accreditation to ISO 15189:2022 for its Oxford histology laboratory, CQC registration for facilities in Oxford and Exeter, and participates in NEQAS/EQA schemes. The company serves the UK market through the NHS National Framework Agreement and operates CLIA-registered facilities in the United States and Canada. With average turnaround times of 1.5 days for primary reporting and 4.0 days for secondary consults, Diagnexia addresses the critical gap where 97% of NHS histopathology departments operate understaffed with 200-300 consultant vacancies nationwide. The service is supported by dedicated case management teams and robust digital integration systems designed specifically for rapid, reliable pathology reporting.
Mission & Story
Founding Story
Founded to address the global diagnostic gap in pathology, particularly focusing on workforce shortages and access to subspecialty expertise in underserved regions.
Clinical Focus
Medical conditions and clinical areas addressed by Diagnexia.
Who It Serves
Milestones & Awards
Recent Milestones
Fifth Diagnexia Histopathology Symposium scheduled for August 2026 at Queen's College; Computational Pathology Fundamentals 2-day course scheduled August 2026; UKAS accreditation to ISO 15189:2022 achieved for Oxford laboratory; NHS Framework supplier status
Awards & Recognition
UKAS accreditation to ISO 15189:2022; ISO 27001 accreditation by BSI; CQC approval for diagnostic screening services; NHS National Framework Agreement supplier status
Key Partnerships
Social & Media
Latest Updates
Thinking Beyond Outsourcing: Designing Embedded Clinical Support
How To Plan For The Diagnostic Backlog No One Sees Coming
AI Has Arrived in Pathology, And It’s Seeing What We Couldn’t
The Numbers No One Wants to Hear
Diagnexia Achieves Full UKAS Accreditation for Oxford Histopathology Laboratory and Digital Pathology Services
Company Details
- Headquarters
- Oxford, England, United Kingdom
Work here?
Claim this listing to update company information and connect with our audience.
Claim This ListingSecurity & Compliance
Official Sources
Similar Companies in this Market
View all 45 →
Aiforia
Aiforia provides AI-powered digital pathology solutions for clinical diagnostics and research. The company offers cloud-based deep learning tools and CE-IVD marked clinical suites for analyzing pathology images across multiple cancer types, serving pathologists, researchers, and diagnostic laboratories worldwide.
Aignostics
Aignostics develops AI-powered pathology solutions for precision medicine, specializing in tumor microenvironment analysis from H&E-stained whole slide images. The company serves life sciences companies and academic researchers with foundation models and custom analytics services.
Aiosyn
Aiosyn develops AI-powered computational pathology software that integrates into standard digital pathology workflows. The company specializes in deep learning solutions for cancer and chronic kidney disease diagnostics, serving clinical laboratories, biopharma, and CROs.
AIxMed
AIxMed develops AI-powered computational cytology platforms for cancer detection and diagnosis. The company's flagship product AIxURO analyzes urine cytology for bladder cancer, with additional platforms in development for thyroid, cervical, and lung cancer screening.
Akoya Biosciences
Akoya Biosciences, now part of Quanterix, provides spatial biology solutions for high-plex tissue analysis. The company develops instruments, assays, and software for spatial proteomics research, enabling researchers to map biomarkers at single-cell resolution in tissue samples.
Caris Life Sciences
Caris Life Sciences is a leading precision medicine company that provides comprehensive molecular profiling for cancer patients. The company combines genomic, transcriptomic, and proteomic data with AI to deliver personalized treatment insights for oncologists and patients.
CellaVision
201-500 employees
CellaVision is a world-leading provider of digital hematology microscopy solutions covering analyzers, instruments, reagents, and software. The company automates workflows in hematology laboratories of all sizes for human and animal blood and body fluid sample analysis.
Clever Culture Systems
Clever Culture Systems develops AI-powered automated microbiology culture plate reading technology for pharmaceutical and clinical laboratories. Their flagship product, APAS Independence, automates the imaging, interpretation, and reporting of microbial growth on culture plates.
Data Accuracy Notice: Company information on HealthAI Central is compiled from public sources and updated regularly. While we strive for accuracy, details such as funding figures, employee counts, and product offerings may change. We recommend verifying critical information directly with the company before making business decisions.